^
Association details:
Biomarker:KRAS amplification
Cancer:Germ Cell Tumors
Drug Class:MEK inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).

Published date:
05/16/2018
Excerpt:
Clinical trials in molecularily-selected pts are warranted for refractory TGCT, particularly the high frequency of KRAS amplification may portend activity of MEK inhibitors.
DOI:
10.1200/JCO.2018.36.15_suppl.4555